Alice Melão, MSc,  —

Boehringer Ingelheim will add Bridge Biotherapeutics’ experimental inhibitor BBT-877 to its portfolio of potential therapies for fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). This follows the completion of a collaboration and global license agreement between the two companies for the development of BBT-877 for…

The Alpha Foundation for the Improvement of Mining Safety and Health has granted $750,000 to a project to investigate how silica, coal, and other mining dusts contribute to the development of progressive lung fibrosis. Led by researchers at the Chicago Mining Education and Research (MinER) Center from the…

A signaling molecule called interleukin-25 (IL-25) was found to support lung fibroblast proliferation and promote lung inflammation and fibrosis in mice, a study shows. The findings suggest that blocking IL-25 may prevent many of the hallmark features of idiopathic pulmonary fibrosis (IPF), representing a new therapeutic target for this…

Distal airway stem cells (DASCs), which can differentiate into bronchioles and alveoli, were found to prevent fibrosis and support tissue regeneration in the lungs of mice. These findings were reported in the study “Distal airway stem cells ameliorate bleomycin-induced pulmonary fibrosis…

Key pharmaceutical and academic leaders in idiopathic pulmonary fibrosis (IPF) will gather at the Third Annual IPF Summit in San Diego to discuss the latest developments in the field. The conference, taking place Aug. 27-29, aims to create a discussion and networking environment to overcome the translational gap…

Plans for a Phase 2 clinical trial of brilaroxazine, the lead candidate by Reviva Pharmaceuticals to treat idiopathic pulmonary fibrosis (IPF), were the focus of a recent and successful meeting between company officials and the U.S. Food and Drug Administration (FDA), Reviva announced. During this pre-Investigational New Drug (IND) Application meeting, the regulatory…

Treatment with Ofev (nintedanib) can significantly extend the survival of patients with idiopathic pulmonary fibrosis (IPF), an analysis of pooled data from six clinical trials shows. The analyis, conducted by an international research team, was published in the journal BMJ Open Respiratory Research, in an article titled “…

The quality of life of people with idiopathic pulmonary fibrosis (IPF) is strongly associated with clinical changes in lung function, comorbidities, disease duration, and overall clinical course of the disease, a study shows. The study, “The clinical course of idiopathic pulmonary fibrosis and its association to quality…

Increased levels of the signaling molecule IFN-gamma in the blood, as well as of other pro-inflammatory proteins and immune-response activators, can contribute to the worsening of acute symptoms in patients with idiopathic pulmonary fibrosis (IPF), a study finds. Therefore, assessment of these particular molecules may help predict IPF acute…

Frailty and geriatric conditions, such as incontinence, dizziness, vision impairment, hearing impairment, and falls, are common among older patients with idiopathic pulmonary fibrosis (IPF), a pilot study finds. Recognition of such commonly associated age-related complications may help identify IPF patients at risk of a poorer outcome, researchers suggest. The study,…